Japan Designates Orphan Status For Novartis' Canakinumab And Kyowa's KW-0761
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare granted orphan status August 11 to two antibody products: canakinumab and KW-0761